CRISPR-enabled point-of-care genotyping for APOL1 genetic risk assessment
Detecting genetic variants enables risk factor identification, disease screening, and initiation of preventative therapeutics. However, current methods, relying on hybridization or sequencing, are unsuitable for point-of-care settings. In contrast, CRISPR-based-diagnostics offer high sensitivity and...
Main Authors: | Greensmith, Robert, Lape, Isadora T., Riella, Cristian V., Schubert, Alexander J., Metzger, Jakob J., Dighe, Anand S., Tan, Xiao, Hemmer, Bernhard, Rau, Josefine, Wendlinger, Sarah, Diederich, Nora, Schütz, Anja, Riella, Leonardo V. |
---|---|
Other Authors: | Massachusetts Institute of Technology. Institute for Medical Engineering & Science |
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group UK
2024
|
Online Access: | https://hdl.handle.net/1721.1/156882 |
Similar Items
-
APOL1-Associated Kidney Disease in Brazil
by: Cristian Riella, et al.
Published: (2019-07-01) -
APOL1 risk variants and kidney disease: what we know so far
by: Tobias August Siemens, et al.
Published: (2018-07-01) -
A CRISPR-based assay for the detection of opportunistic infections post-transplantation and for the monitoring of transplant rejection
by: Kaminski, Michael M., et al.
Published: (2020) -
Small non-coding RNAs: from trash to treasure
by: Cristian V. Riella -
A pragmatic approach to selective genetic testing in kidney transplant candidates
by: Pitchaphon Nissaisorakarn, et al.
Published: (2024-01-01)